London, UK--(Marketwire - December 11, 2008) - LONDON, UK, 11 December 2008 -- SkyePharma PLC (LSE: SKP) and its partner, Somnus Therapeutics, Inc., today announce the successful completion of the first Phase I trial of their controlled release sleep maintenance product, SKP-1041. Under the terms of the agreement between SkyePharma and Somnus, a USUSD1 million milestone payment is now payable to SkyePharma.
